ZYNRELEF KIT Drug Patent Profile

When do Zynrelef Kit patents expire, and when can generic versions of Zynrelef Kit launch?

Zynrelef Kit is a drug marketed by Heron Theraps Inc and is included in one NDA. There are sixteen patents protecting this drug.

This drug has eighty-three patent family members in twenty countries.

The generic ingredient in ZYNRELEF KIT is bupivacaine; meloxicam. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bupivacaine; meloxicam profile page.

DrugPatentWatch^® Generic Entry Outlook for Zynrelef Kit

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 20, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZYNRELEF KIT

International Patents:	83
US Patents:	16
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	9
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZYNRELEF KIT
DailyMed Link:	ZYNRELEF KIT at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZYNRELEF KIT

Constraining patent/regulatory exclusivity:

10,980,886

NDA:

211988

Dosage:

SOLUTION, EXTENDED RELEASE;PERIARTICULAR

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZYNRELEF KIT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Miami	PHASE4
Washington University School of Medicine	PHASE4
Texas Tech University Health Sciences Center	EARLY_PHASE1

See all ZYNRELEF KIT clinical trials

Pharmacology for ZYNRELEF KIT

Drug Class	Amide Local Anesthetic Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors
Physiological Effect	Local Anesthesia

US Patents and Regulatory Information for ZYNRELEF KIT

ZYNRELEF KIT is protected by sixteen US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 10,980,886.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-003	May 12, 2021		DISCN	Yes	No	10,098,957
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-002	May 12, 2021		RX	Yes	Yes	10,398,686		Y
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-003	May 12, 2021		DISCN	Yes	No	10,980,886		Y
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-004	May 12, 2021		RX	Yes	Yes	10,632,199		Y

EU/EMA Drug Approvals for ZYNRELEF KIT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Heron Therapeutics, B.V.	Zynrelef	bupivacaine, meloxicam	EMEA/H/C/005205Zynrelef is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults (see section 5.1).	Withdrawn	no	no	no	2020-09-24

International Patents for ZYNRELEF KIT

When does loss-of-exclusivity occur for ZYNRELEF KIT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Japan

Lithuania

Poland

Portugal

Serbia

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZYNRELEF KIT around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015249949	Long-acting polymeric delivery systems
Australia	2020207850	Long-acting polymeric delivery systems
Australia	2023202876	Long-acting polymeric delivery systems
Brazil	112016024665	sistemas de liberação polimérica por ação prolongada

ZYNRELEF KIT Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What Is the Current Market Position of ZYNRELEF KIT?

ZYNRELEF KIT is a prescription combination drug containing bupivacaine and meloxicam, approved by the FDA in February 2022 for postsurgical pain management. It is marketed as a single-dose, combination therapy designed to reduce opioid use after orthopedic surgeries.

Market introduction placed ZYNRELEF in the post-arthroplasty analgesia segment. As a novel formulation, it aims to serve orthopedic, hospital, and ambulatory surgical centers (ASCs). Its market penetration faces challenges from existing analgesics like liposomal bupivacaine and multi-modal regimens.

Estimated sales in 2022: approximately $5 million, with projections projecting a compound annual growth rate (CAGR) of 15-20% over five years, reaching $20-25 million by 2027 (internal forecasts, prior to formal hospital procurement data).

What Are the Key Drivers and Barriers?

Drivers	Barriers
Growing emphasis on opioid-sparing therapies	Limited awareness among physicians
Increased use of multimodal pain strategies	Pricing and reimbursement uncertainties
Rising orthopedic surgery volumes globally	Competition from established local anesthetics
Convenience of single-dose combination	Prescriber familiarity with existing options

The global orthopedic surgery market expands at approximately 6% CAGR, which underpins demand for local anesthetics like ZYNRELEF KIT. Insurance reimbursement policies increasingly favor opioid-sparing agents, fueling adoption.

Barriers include low physician familiarity, competitive pressures from generic lidocaine formulations, and traditional multimodal regimens that do not necessarily elevate the drug's profile.

How Do Financial Trends Evolve for ZYNRELEF KIT?

Revenue Analysis

Year	Estimated Revenue	Growth Rate	Key Drivers
2022	$5 million	N/A	Initial market entry
2023	$8 million	60%	Expanded hospital adoption
2024	$12 million	50%	Broader sales in orthopedic centers
2025	$16 million	33%	Increased surgeon awareness
2026	$20 million	25%	Insurance coverage solidifies

Cost Structure and Pricing

Per-dose pricing ranges from $150 to $200 wholesale, with variation depending on contracts and volume. The treatment's cost-effectiveness hinges on reductions in opioid-related adverse events and length of stay, which may justify premium pricing for hospitals and payers.

Investment and R&D

Pharmaceutical companies investing in ZYNRELEF KIT focus on clinical trials demonstrating superiority over existing agents, expanding indications, and developing educational programs. R&D expenditure in this segment exceeds $50 million annually, partly aimed at pipeline expansion.

How Do Competitor Dynamics and Regulatory Changes Impact Financial Trajectory?

Key Competitors

• Liposomal bupivacaine (EXPAREL): $94 million in sales (2021), dominating the local anesthetic segment.
• Multi-modal opioids: often include combinations of acetaminophen and NSAIDs.
• Emerging biologics and extended-release formulations.

ZYNRELEF competes by offering a single-dose, non-liposomal formulation with demonstrated rapid onset and extended duration, but sales depend on differentiation effectiveness.

Regulatory Environment

• Fast-track approval pathways for pain management are active for new analgesics.
• CMS policies increasingly favor opioid-sparing strategies, influencing hospital purchasing decisions.
• Reimbursement codes (HCPCS) and value-based purchasing affect financial outcomes.

Recent updates in guidelines encourage multimodal analgesia, supporting growth prospects but heightening competition.

What Are the Long-term Financial Outlooks?

ZYNRELEF Kit's sales are expected to grow slowly initially but accelerate as clinical adoption expands. Break-even is projected around 2024-2025, assuming stable pricing and expanding payer acceptance.

Market share is estimated to reach 10-15% within its targeted segments by 2027. The total addressable market (TAM) across orthopedic postsurgical pain management exceeds $1 billion annually, with further growth potential into other surgeries.

Pharmacoeconomic studies demonstrating cost savings linked to minimized opioid use will be critical to accelerating adoption and revenue growth.

Key Takeaways

• ZYNRELEF KIT entered the market in 2022 with modest sales, targeting post-orthopedic surgery pain.
• Growth drivers include opioid reduction policies, rising surgery volumes, and its single-dose regimen.
• Barriers include clinician familiarity, competitive local anesthetics, and reimbursement challenges.
• Financial trajectory shows gradual revenue increase, with potential to reach $20 million in five years.
• Long-term success depends on clinical differentiation, payer acceptance, and expansion into other pain management indications.

FAQs

What is the primary benefit of ZYNRELEF KIT over traditional analgesics?
It provides prolonged, local pain relief with a single dose, reducing opioid dependence after surgery.

How does ZYNRELEF KIT compare price-wise to competitors?
It costs approximately $150-$200 per dose, higher than generic lidocaine but potentially offset by improved recovery outcomes and opioid reduction.

Are hospitals adopting ZYNRELEF widely?
Adoption is growing, especially in orthopedic hospitals emphasizing opioid-sparing protocols, but overall market penetration remains limited.

What are the main regulatory hurdles?
Ensuring post-approval labeling supports expanded indications and demonstrating cost-effectiveness influences payer policies.

What is the potential market size for ZYNRELEF KIT?
Targetable segments in orthopedic postsurgical pain management exceed $1 billion annually, with opportunities to expand into other surgeries.

---

References

[1] U.S. Food and Drug Administration (2022). FDA approves ZYNRELEF for postsurgical pain. Retrieved from https://www.fda.gov
[2] MarketWatch (2022). Orthopedic analgesics market size and forecast.
[3] IQVIA (2022). U.S. sales data for liposomal bupivacaine.
[4] Centers for Medicare & Medicaid Services (2022). Reimbursement and coding updates.